UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of **May 2020**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein are the following exhibits:

99.1 Press Release: Evogene Launches its New Branding to Reflect the Company's Expanded Vision and New Business Model.

99.2 Evogene Investor Presentation – May 2020.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: May 20, 2020

By: /s/ Dorit Kreiner

Dorit Kreiner
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Press Release: Evogene Launches its New Branding to Reflect the Company's Expanded Vision and New Business Model.
99.2	Evogene Investor Presentation – May 2020.

Exhibit 99.1

Evogene Launches its New Branding to Reflect the Company's Expanded Vision and New Business Model

Rehovot, Israel – May 20, 2020 – Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces today its rebranding. The new corporate identity reflects the company's expanded vision and new business model.

"Evogene has undergone a significant transformation in its offering over the past years, and we are actively working to portray our expanded vision and strategy to the business and investment community. I believe that this new branding represents our new offering and will serve us extremely well in communicating this to the broader market," **stated Ofer Haviv, President & CEO of Evogene.**

Established as a spin-off from Compugen Ltd. in 2002, Evogene was initially focused on applying its capabilities in computational biology in agriculture, and more specifically on improving seed traits based on genomic modification. Changes in the agriculture market and in consumer tastes and demand necessitated that Evogene broaden its vision and focus on several new target markets and segments. The significant capital raised in its 2013 IPO allowed the Company to execute this strategy, enhancing its technology and expanding to new market segments.

In the years that followed, the Company's management took a series of steps that paved the path for its evolution. Two key decisions underlay this development; the first was expanding Evogene's technological capabilities in computational biology to include development of products based on microbes and small molecules, in addition to genomics, and the second was to expand Evogene's focus beyond agriculture, to human health. These decisions led to the creation of Evogene's amassed computational biology capabilities – the CPB (Computational Predictive Biology) platform, which aims to substantially increase the probability of success, while reducing time and cost, of life-science product development. In parallel, the Company established diverse internal divisions, each leading the development of specific market-driven products while using the CPB platform as their competitive advantage.

In 2018, Evogene announced the revision of its corporate structure to accommodate its new broadened activities. The Company began the execution of this plan by establishing new dedicated subsidiaries, based on the activities of its existing divisions, focusing on downstream product development. Four new subsidiaries were established in the areas of human health and agriculture, including (in order of establishment): Biomica, AgPlenus, Lavie Bio and Canonic, joining Evogene's previous subsidiary, Casterra. In parallel, Evogene continued to focus on improvements to its CPB platform, serving as a technological hub to be used by the whole group through licensing agreements.

Mr. Haviv continued, "Today, Evogene provides tailor-made computational-biology solutions for the discovery and development of products based on microbes, small molecules and genetic elements for life-science based industries, including: human health, agriculture and industrial applications.

"I believe that we are better-positioned than ever before to capture the value of our unique technology in two distinct ways – through our existing collaborations and through our independent subsidiaries. We have several upcoming key milestones across our subsidiaries, which we believe will generate substantial value. Details on these milestones are available in our newly branded presentation, filed today.

"We are now ready to continue to harness the power of our CPB platform through additional collaborations with strategic partners and to benefit as a shareholder from our subsidiaries as their value is unlocked and becomes apparent." - **Mr. Haviv concluded.**

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN.TA) is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the C*omputational Predictive Biology* (*CPB*) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the *CPB* platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

For more information, please visit www.evogene.com

Forward Looking Statements:

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. For example, Evogene is using forward-looking statements in this press release when it discusses capturing the value of its technologies, entering into collaboration agreements and its upcoming milestones. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom and those risk factors contained in Evogene's reports filed with the applicable securities authorities. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Contact:

Rivka Neufeld
Investor Relations and Public Relations Manager
E: IR@evogene.com
T: +972-8-931-1940

US Investor Relations:

Joseph Green
Edison Group
E: jgreen@edisongroup.com
T: +1 646-653-7030

Laine Yonker
Edison Group
E: lyonker@edisongroup.com
T: +1 646-653-7035

Exhibit 99.2


evogene
DECODING BIOLOGY
DECODING BIOLOGY
INVESTOR PRESENTATION
May 2020

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For example, Evogene is using forward-looking statements in this presentation when it discusses its near-term value drivers, including statements to the effect that it will reach commercialization, regulatory approval or enter into collaboration agreements; its milestones for each of 2020, 2021 and 2022; its belief that its diverse portfolio mitigates the risk associated with each individual opportunity within its portfolio and in its product pipeline; and its estimated cash usage for its year ending December 31, 2020. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom, the extent of Evogene continuing to maintain its holdings in its subsidiary companies, whether Evogene is able to comply with regulatory requirements, the degree of Evogene's success at adapting to the continuous technological changes in its industries, and those factors and risks described in greater detail in Evogene's Annual Report on Form 20-F and in other reports it files and furnishes with the U.S. Securities and Exchange Commission and the Israel Securities Authority from time to time. In addition, Evogene relies, and expects to continue to rely, on third parties to conduct certain activities, such as its field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene may experience significant delays in the conduct of its activities. All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Agenda

- Introduction
- Fields of activity
- Technology
- Summary

Annex I - Evogene's Main Subsidiaries

Annex II - Financial Fundamentals




INTRODUCTION
evogene
DECODING BIOLOGY
4


OUR VISION
Revolutionizing life-science product development utilizing cutting edge computational biology technologies.
DECODING BIOLOGY

Life-science product development challenges

High cost, long time-to-market and low probability of success

Ag-chemicals Industry

Discovery and development costs of a new crop protection product



Source: Phillips McDougall, 2016

Time to develop a new crop protection product

	1995	2000	2005-8	2010-15
Number of years between the first synthesis and first sale of product	8.3	9.1	9.8	11.3

Source: Phillips McDougall, 2016

Pharmaceutical Industry

CDER'S* annual novel drug approvals: 2010-2019



Source: U.S. Food and Drug Administration

Worldwide total pharmaceutical R&D spend in 2010-2024



Source: Evaluate Pharma May 2019

*Center for Drug Evaluation and Research

The opportunity

Utilize comprehensive and integrated computational biology to substantially increase the probability of success, while reducing the time and cost of life-science product development.

When biology meets disruptive technologies; introducing–

CPB platform

Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), seeking to successfully discover & develop novel life-science based products.

Developed over two decades at an investment of tens of millions of dollars and validated through collaborations with industrial leaders

CPB - Computational Predictive Biology



The power of the CPB platform

Discovery

Computational selection of the most promising candidates to initiate the product development process.

Development

Computational driven solution addressing optimization development challenges for the selected candidates, supporting the way to successful commercialization.



Tailor-made **solutions** for product development

The CPB platform provides tailor-made **solutions** for discovery and development for life-science products based on the following three core components:

- Microbes
- Small molecules
- Genetic elements



Business Model



1

Collaborations

Joint development with leading companies for defined products utilizing Evogene's unique solution. Later-stage development and commercialization of the product will likely be done by the partner.

Potential revenue for Evogene

- Licensing and research payments
- Milestone payments
- Revenue sharing

2

Subsidiaries

Establish independent entities focusing on a defined commercial field with an exclusive license to use Evogene's unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategic collaborations.

Potential revenue for Evogene

- Licensing and research payments
- Consolidated revenues
- Dividends (subject to profits generated by subsidiary)
- Sale of equity


FIELDS OF ACTIVITY
evogene
DECODING BIOLOGY 12

Potential fields of activity



	HUMAN HEALTH	AGRICULTURE	INDUSTRIAL APPLICATIONS
MICROBES			
SMALL MOLECULES			
GENETIC ELEMENTS			

Current life-science based products under development



	HUMAN HEALTH	AGRICULTURE	INDUSTRIAL APPLICATIONS
MICROBES	Microbiome based Therapeutics	Ag-Biologicals	
SMALL MOLECULES		Ag-Chemicals	
GENETIC ELEMENTS	Medical Cannabis	Seed Traits	Ag-solutions for castor oil production



Development & commercialization through subsidiaries and collaborations





	HUMAN HEALTH	AGRICULTURE	INDUSTRIAL APPLICATIONS
MICROBES	BIOMICA	lavie bio	
SMALL MOLECULES		agPlenus	
GENETIC ELEMENTS	CANONIC	Seed Traits [division]	casterra

Subsidiaries - expected main near-term value drivers

	2020		2021		2022
BIOMICA	Extend pre-clinical study in immuno-oncology program	Initiate first GMP production of drug candidates in immuno-oncology program	Extend pre-clinical study in Inflammatory Bowel Disease (IBD) program	Proof of concept, first in man study, in the immuno-oncology program	
CANONIC*	Engagement with commercial partners for cultivation and production	Demonstrate yield improvement in cannabis lines under development	Pre-commercial activity towards commercialization in 2022	Demonstrate clinical effects of a developed line, based on dedicated research with a medical institution	INITIAL SALES
agPlenus	Sign collaboration based on pre-Lead candidates from herbicide program	Reach a 'Lead' in herbicide program	Reach a POC for a herbicide tolerance gene trait, for a 'Lead' herbicide in development	Licensing agreement of 'Lead' herbicide candidate	
lavie bio	Advance phase in bio-pesticide & bio-stimulant programs	File for regulatory approval for a wheat bio-stimulant product	Receive regulatory approval for a wheat bio-stimulant product	Advance a wheat bio-stimulant product to pre-commercial activities with early-adopter farmers	INITIAL SALES

Pipeline Regulation Collaboration Commercialization

* Additional milestone on slide 35

TECHNOLOGY

The **challenge** in creating life-science based products

The **challenge** in creating life-science based products

Common practice

Discovery – selection of product candidates mainly addressing efficacy

Product Definition → **Candidate Selection** | Efficacy | Safety | Selectivity | Shelf-life | Other | **Product Launch**

The **challenge** in creating life-science based products

Common practice

Discovery – selection of product candidates mainly addressing efficacy

Development – inefficient optimization & difficulty in addressing a single challenge without impairing others

X Low probability of success

X Long time to market

X High development costs

Evogene's solution:
Discovery

A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI.

Evogene's solution: Development

A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes.

Evogene's tailor-made solution

Discovery

Computational prediction of candidates, to serve as the **product's core-component**, addressing multiple key product attributes.

Development

Computational driven solution for guiding and assessing the optimization process of the **selected core component**, without impairing other key product attributes.

MICROBOOST^{AI}

CHEMPASS^{AI}

GENERATOR^{AI}


SUMMARY
evogene
DECODING BIOLOGY 24

Evogene group

CPB

evogene
DECODING BIOLOGY

Human Health

BIOMICA

Microbiome based Therapeutics

- Immuno-oncology
- GI- gastrointestinal-related disorders
- MDRO – multi-drug resistant organisms

90%*

CANONIC

Medical Cannabis

- Stable high yield of specific compounds
- Stable high yield of total compounds

100%*

Agriculture

agPlenus

Ag Chemicals

- Herbicides
- Insecticides
- Fungicides

100%*

lavie bio

Ag Biologicals

- Bio-Stimulants
- Bio-Pesticides

72%*

Seed Traits

- Yield improvement and drought tolerance
- Plant disease
- Insect control

Internal division of Evogene

Industrial Applications

casterra

Castor Oil Production

- Castor seeds & growth protocol

100%*

*Evogene holdings in its applicable subsidiaries

Investment highlights

Technological platform and diverse product portfolio to mitigate the risk associated with life-science investments

Evogene offers the opportunity to invest in the technology of tomorrow, while its and its subsidiaries' diverse and advanced product portfolios may mitigate the risk associated with an individual opportunity.

Value creation through subsidiary

Example #1

In August 2019, Lavie Bio, secured a strategic investment from Corteva:

- $10 million dollars in cash, and transfer of Corteva Inc.'s holdings in its subsidiary, Taxon Biosciences.
- in exchange for ~ 28% of Lavie Bio's shares.

Value creation through subsidiary

Example #2

Wholly owned subsidiary, AgPlenus, recently entered into a strategic collaboration with Corteva for the development of a new MoA (Mode-of-Action) herbicide.

Significant milestones expected

Biomica - Proof of concept, first in man study, in the immuno-oncology program, expected in 2021.

Canonic - Pre-commercial activity expected in 2021. Commercialization expected in 2022.

AgPlenus – Reach 'Lead' chemical, the basis for a new MoA herbicide, expected in 2020.

Lavie Bio – Advancement of a wheat bio-stimulant to pre-commercial activities with early-adopter farmers, expected in 2021. Commercialization expected in 2022.


THANK YOU!
evOgene
DECODING BIOLOGY



Annex I: Evogene's Main Subsidiaries


HUMAN HEALTH
BIOMICA | CANONIC

BIOMICA | Human Microbiome

Biomica's Mission

Discovery and development of novel therapies for microbiome-related human disorders using computational biology.

Product Pipeline

Immuno-oncology

BMC121 | Combination therapy for cancer with checkpoint inhibitors

BMC127 | Combination therapy for cancer with checkpoint inhibitors

GI related disorders

BMC321 | Inflammatory Bowel Disorder (IBD)

BMC322 | Inflammatory Bowel Disorder (IBD)

BMC426 | Irritable Bowel Syndrome (IBS)

MDRO (Multi Drug resistant organisms)

BMC201 | Clostridioides difficile infection (CDI)

BIOMICA

Immuno-Oncology Program – Preparation towards the anticipated first in man proof of concept clinical trials

(January 2020)

Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program

The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials

Rehovot, Israel – January 13, 2020

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for the scale-up production of its drug candidates, microbial consortia BMC121 & BMC127 for its Immuno-Oncology program. This agreement will accelerate the Company's Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies.

Biose Industrie is a drug-GMP certified manufacturer of bacteria-based APIs and clinical and commercial products. Biomica engaged with Biose for the scale-up development and GMP production of a clinical batch of its drug candidates.

BIOMICA

Milestones

2020

- Extend pre-clinical study in immuno-oncology program.
- Initiate first GMP production of drug candidates immuno-oncology program.

2021

- Proof of concept, first in man study, in the immuno-oncology program.
- Extend pre-clinical study in IBD program.

CANONIC | Medical Cannabis

Canonic's Mission

Commercialize precise & stable medical cannabis products for better therapeutic effects using computational biology.

Product Pipeline

MetaYield

Stable enhancement of total plant compounds

- Increased compounds per plant
- Increased compounds per area

Precise

Stable enhancement of specific active compounds

- Medical indication focus
- Compound profile focus

CANONIC

Initiation of Breeding and Cultivation of Cannabis Varieties with Unique Genomic Profiles

(November 2019)

Canonic Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products

This announcement follows successfully importing a collection of widely genetically diverse cannabis lines, establishing specialized R&D facilities, and receiving regulatory approval from the Israeli Medical Cannabis Agency (IMCA)

Rehovot, Israel – November 6, 2019

Canonic, a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN) focused on the development of medical cannabis products, announces today the initiation of its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. The initiation of cannabis cultivation follows: (1) successfully importing widely genetically diverse cannabis lines originating from different territories, (2) establishment of cannabis dedicated R&D facilities, including greenhouses, a molecular lab and tissue culture rooms and (3) receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency (IMCA).

CANONIC

Milestones

2020

- Demonstrate yield improvement in cannabis lines under development.
- Engagement with commercial partners for cultivation and production.
- Conduct pre-clinical studies to support the development of Canonic's medical cannabis products.

2021

- Pre-commercial activity with first cannabis variety towards commercialization in 2022.
- Demonstrate clinical effects of Canonic varieties based on dedicated research with a medical institution.


AGRICULTURE
AgPlenus | Lavie Bio

agPlenus | Ag-Chemicals

AgPlenus Mission

Design of next generation effective, sustainable and safer crop protection products by leveraging computational biology.

Product Pipeline

Herbicide

Novel MOA (Mode-of-Action)

Existing MOA optimization

Insecticide

Novel SoA (Site-of-Action)

AI optimization

Fungicide

Existing MOA optimization

Strategic collaboration with Corteva for the development of novel herbicides

(March 2020)

Corteva Agriscience and AgPlenus Announce Collaboration for the Development of Novel Herbicides

Collaboration to address rise in global weed resistance using Corteva's product discovery and development expertise and AgPlenus' internal novel herbicide pipeline

Wilmington, DE., USA and Rehovot, Israel – March 25, 2020

Corteva Agriscience (NYSE: CTVA), a leading pure-play agriculture company, and AgPlenus, a subsidiary of Evogene Ltd., (NASDAQ: EVGN, TASE: EVGN), today announced that they have entered into a multi-year collaboration for the development of novel herbicides. The collaboration will combine Corteva's strengths in crop protection product discovery and development with AgPlenus' expertise in designing effective and sustainable crop protection products using predictive biology.

By leveraging their complementary expertise, Corteva and AgPlenus will address the rise of global weed resistance, created in-part by the absence of new modes of action (MoAs) for weed control over the past 30 years. Successful products resulting from the collaboration will enter a multi-billion-dollar market.

agPlenus

Milestones

2020

- Sign collaboration based on pre-Lead candidates from herbicide program.
- Reach a 'Lead' in herbicide program.

2021

- Reach a POC for a herbicide tolerance gene trait, for a 'Lead' herbicide in development.
- Licensing agreement of 'Lead' herbicide candidate.



lavie bio | Ag Biologicals

Lavie Bio Mission

Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products using computational biology.

Product Pipeline

Bio-Stimulants

Wheat

Corn

Bio-Pesticides

Mildew, fruit rots

Fusarium and seedlings disease

Bio-Insecticides

Corteva Investment in Lavie Bio

Corteva's investment included its holdings in its wholly owned subsidiary Taxon Biosciences and $10 million to Lavie Bio.

(August 2019)

Corteva Agriscience to Invest in Evogene's Agriculture Biologicals Subsidiary, Lavie Bio

Investment Includes Equity and Corteva's Shares in Taxon Biosciences for Shares in Lavie Bio

Wilmington, Del., USA and Rehovot, Israel – Aug. 7, 2019

Corteva, Inc. (NYSE: CTVA), a leading pure-play agriculture company, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Corteva will make an investment in Evogene's agriculture biologicals subsidiary, Lavie Bio (Lavie). The transaction includes the exchange of all shares of Corteva's wholly owned subsidiary Taxon Biosciences along with an equity investment by Corteva in Lavie. As consideration for the Taxon Biosciences shares and equity investment, Corteva will be issued approximately 30 percent of Lavie's equity while Evogene will hold approximately 70 percent of Lavie's equity.

Taxon Biosciences' capabilities are expected to provide significant synergetic value to Lavie and accelerate the development of Lavie's products. Taxon Biosciences' assets, including a large microbial collection and product candidate pipeline, will be integrated into Lavie's pipeline, accelerating Lavie's 'biology driven design' approach and its product development.

lavie bio

Milestones

2020

- Advance phase in bio-pesticide & bio-stimulant programs.
- File for regulatory approval for a wheat bio-stimulant product.

2021

- Receive regulatory approval for a wheat bio-stimulant product.
- Advancement of a wheat bio-stimulant to pre-commercial activities with early-adopter farmers.

Annex II:
Financial Fundamentals

Key Financials: Balance Sheet

Thousands of US $	31.12.2019	31.12.2018
Current Assets	49,027	55,488
Long-Term Assets	22,337*	3,206
Total Assets	**71,364**	**58,694**
Current Liabilities	5,729	5,431
Long-Term Liabilities	5,418	2,957
Equity attributable to equity holders of the Company	50,144	50,053
Non-controlling interest	10,073	253
Total Liabilities & Shareholders Equity	**71,364**	**58,694**

*~$17 million attributed to intangible assets (net) following Corteva's investment in Lavie Bio

Key Points:

- Consolidated cash position: ~$47 million as of 31.12.2019
- No debt
- Estimated net cash usage for 2020 (without Lavie Bio): $14-$16 million
- Listed on TASE (2007) and NASDAQ (2013)